Marius Petrulionis
Overview
Explore the profile of Marius Petrulionis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luksaite-Lukste R, Gecaite I, Marcinkeviciute K, Dumskis E, Samuilis A, Zvirblis T, et al.
J Clin Med
. 2024 Jun;
13(12).
PMID: 38929896
-The objective was to compare the effectiveness of observation in standard-of-care computed tomography (CT) in adult patients with suspected acute appendicitis (AA). -Patients with clinically suspected AA and inconclusive diagnosis...
2.
Petrauskas V, Poskus E, Luksaite-Lukste R, Kryzauskas M, Petrulionis M, Strupas K, et al.
Front Surg
. 2022 Jul;
9:896206.
PMID: 35800113
Purpose: COVID-19 posed an unprecedented modern global healthcare crisis affecting both elective and urgent surgeries. The aim of this study is to evaluate the difference in the presentation of acute...
3.
Kavaliauskas P, Dulskas A, Kavaliauskaite R, Dailidenas S, Petrulionis M, Samalavicius N
Asian J Surg
. 2021 May;
44(7):1027-1028.
PMID: 34045129
No abstract available.
4.
Prades J, Arnold D, Brunner T, Cardone A, Carrato A, Coll-Ortega C, et al.
ESMO Open
. 2020 Nov;
5(6):e001051.
PMID: 33188052
Pancreatic cancer is one of the most lethal tumours, and it is the fourth cause of cancer death in Europe. Despite its important public health impact, no effective treatments exist,...
5.
Ger M, Kaupinis A, Petrulionis M, Kurlinkus B, Cicenas J, Sileikis A, et al.
Anticancer Res
. 2018 Oct;
38(10):5759-5765.
PMID: 30275197
Background/aim: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer, particularly due to its aggressive course and challenging diagnostics in early-stage disease. The aim of this study...
6.
Rackauskas R, Mikalauskas S, Petrulionis M, Poskus T, Jotautas V, Stanaitis J, et al.
Wideochir Inne Tech Maloinwazyjne
. 2017 Jul;
12(2):120-124.
PMID: 28694896
Introduction: Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most frequent cause of cancer-related death in the world. CRC screening programs have been widely introduced...
7.
Lin S, Hoffmann K, Gao C, Petrulionis M, Herr I, Schemmer P
J Pineal Res
. 2017 Feb;
62(3).
PMID: 28178378
Melatonin has been shown to exert anticancer activity on hepatocellular carcinoma (HCC) through its antiproliferative and pro-apoptotic effect in both experimental and clinical studies, and sorafenib is the only approved...
8.
Tumas J, Kvederaviciute K, Petrulionis M, Kurlinkus B, Rimkus A, Sakalauskaite G, et al.
Med Oncol
. 2016 Nov;
33(12):133.
PMID: 27807722
Pancreatic cancer is one of the worst prognoses of all malignancies. More than 40,000 deaths a year from this disease are observed in European Union alone. The only possibly curative...
9.
Poskus E, Platkevicius G, Simanskaite V, Rimkeviciute E, Petrulionis M, Strupas K
Medicina (Kaunas)
. 2016 Oct;
52(5):321-324.
PMID: 27707579
Merkel cell carcinoma is an aggressive skin malignancy. Primary Merkel cell carcinomas are treated by wide radical excision with or without adjuvant radiotherapy, while benefits of adjuvant chemotherapy remain doubtful....
10.
Yamanaka K, Petrulionis M, Lin S, Gao C, Galli U, Richter S, et al.
Cancer Med
. 2014 Jan;
2(6):862-71.
PMID: 24403259
Everolimus is an orally administrated mammalian target of rapamycin (mTOR) inhibitor. Several large-scale randomized controlled trials (RCTs) have demonstrated the survival benefits of everolimus at the dose of 10 mg/day...